Incyte Dl 001【ICY】銘柄情報

Incyte Dl 001 (ICY) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

102.55

( 0.29% )

買値

102.05

売値

103.00

出来高

101.75 日の範囲 102.75

57.02 52 週間の範囲 103.10

時価総額

20.488B

前日終値

102.25

始値

102.75

時刻

101.85

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

1,662,504 €

発行済株式数

199,782,155

配当利回り

PER

16.12

1 株当たり利益 (EPS)

7.06

歳入

5.36B

純利益

1.43B

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-vers... Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company’s clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

www.incyte.com

本社

Wilmington, United States

設立

1991

Incyte Dl 001 is listed in the Healthcare sector of the Tradegate (DE) with ticker ICY. The last closing price for Incyte Dl 001 was 102.25 €. Over the last year, Incyte Dl 001 shares have traded in a share price range of 57.02 € to 103.10 €.

Incyte Dl 001 currently has 199,782,155 shares in issue. The market capitalisation of Incyte Dl 001 is 20.49 € billion. Incyte Dl 001 has a price to earnings ratio (PE ratio) of 16.12.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	7.31	7.67534649307	95.24	103.1	95.24	858	99.99712587	DE
4	15.57	17.90066682	86.98	103.1	83.78	578	94.52378371	DE
12	20.05	24.303030303	82.5	103.1	75.5	517	87.3556532	DE
26	15.81	18.2268849435	86.74	103.1	75.5	539	86.74785291	DE
52	44.43	76.445285616	58.12	103.1	57.02	520	83.91420552	DE
156	42.83	71.7180174146	59.72	103.1	47.3	433	69.92215109	DE
260	42.83	71.7180174146	59.72	103.1	47.3	433	69.92215109	DE